BlossomHill Therapeutics, Inc. (BLSM) Income Statement
BLSM 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBLSM revenue and net income
BLSM growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BLSM quarterly EPS vs estimates
BlossomHill Therapeutics beat the analyst EPS estimate in 0 of the last 1 quarters.
BLSM income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $0 | $0 |
| Research & development | $56.1M | $31.8M |
| Sales, general & admin | $7.9M | $4.6M |
| Total operating expenses | $64.0M | $36.4M |
| Operating income | −$64.0M | −$36.4M |
| Interest income | $3.5M | $5.7M |
| Income before taxes | −$60.6M | −$30.7M |
| Net income | −$60.6M | −$30.7M |
| EBITDA | −$63.6M | −$36.1M |
| EPS (diluted) | −$2.08 | — |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research & development | $21.4M | $19.9M | $12.5M | $9.6M |
| Sales, general & admin | $3.3M | $2.2M | $1.6M | $1.9M |
| Total operating expenses | $24.7M | $22.1M | $14.1M | $11.5M |
| Operating income | −$24.7M | −$22.1M | −$14.1M | −$11.5M |
| Interest income | $915,000 | $1.1M | $859,000 | $976,000 |
| Income before taxes | −$23.8M | −$21.0M | −$13.2M | −$10.5M |
| Net income | −$23.8M | −$21.0M | −$13.2M | −$10.5M |
| EBITDA | −$24.7M | −$22.0M | −$14.0M | −$11.4M |
| EPS (diluted) | −$8.75 | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BLSM's financial statements (latest annual report filed December 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BLSM financial results
BlossomHill Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $60.6 million. Diluted earnings per share came to −$2.08.
See the BLSM stock overview for the latest quote and news, or the BLSM chart for price history and technical indicators.
BLSM income statement FAQ
Does BlossomHill Therapeutics have revenue?
BlossomHill Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is BlossomHill Therapeutics profitable?
No. BlossomHill Therapeutics reported a net loss of $60.6 million in fiscal 2025.
How much does BlossomHill Therapeutics spend on research and development?
BlossomHill Therapeutics spent $56.1 million on research and development in fiscal 2025.
What are BlossomHill Therapeutics's earnings per share?
BlossomHill Therapeutics earned $-2.08 per diluted share in fiscal 2025.
When does BlossomHill Therapeutics's fiscal year end?
BlossomHill Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on December 31, 2025.